Recent developments highlight Mangoceuticals' expansion through patent acquisitions, new product launches, and exclusive distribution agreements, alongside research advancements in antiviral and respiratory illness prevention.

• Mangoceuticals expanded its patent portfolio in nutraceuticals, enhancing its intellectual property assets [N1].
• The company reported 100% survival rates in field studies of MGX-0024 for poultry respiratory diseases, indicating progress in its antiviral research [N2].
• Mangoceuticals entered the wellness pouch market and appointed Tim Corkum to lead the new unit, signaling diversification of product offerings [N3].
• The company acquired intellectual property assets from Smokeless Technology Corp. to expand into the oral pouch delivery market [N4].
• Mangoceuticals secured exclusive rights for the plant-based nutriceutical Diabetinol® targeting pre-diabetes and weight management in the U.S. and Canada [N5].
• Launched PeachesRx, a women's telehealth brand focused on wellness and GLP-1 treatments, expanding its telehealth services [N6].
• Advanced research on respiratory illness prevention technologies targeting avian influenza and antiviral research on avian flu prevention for poultry [N7][N8].
• Signed exclusive distribution agreements for its Dermytol® skincare line, expanding its market reach [N7].

Mangoceuticals has demonstrated progress in expanding its product portfolio through acquisitions and new market entries, including telehealth wellness brands and nutraceuticals. The company has secured exclusive rights to innovative products and intellectual property, and reported positive field study results for its antiviral poultry respiratory disease treatment. Its agreements with a related-party pharmacy provide a broad operational footprint across most U.S. states. These factors contribute to a diversified product offering and potential for market penetration in emerging health and wellness segments.

The company faces significant challenges including recurring net losses, limited liquidity with current liabilities exceeding current assets, and non-compliance with Nasdaq listing requirements due to low stock price. Regulatory scrutiny of its compounding pharmacy model and telehealth prescribing practices poses risks of enforcement actions and operational disruptions. Dependence on a related-party pharmacy and third-party logistics providers adds operational risk. The company's limited operating history and need for additional capital raise concerns about its ability to sustain operations and execute growth strategies.

Mangoceuticals' moat is primarily based on its proprietary compounded pharmaceutical products, exclusive intellectual property acquisitions, and strategic partnerships such as the related-party pharmacy agreement with Epiq Scripts, which provides a broad geographic reach through licensing in 49 states and the District of Columbia. The company's expansion into telehealth-enabled wellness services and nutraceuticals, including exclusive rights to plant-based products, adds differentiation. However, the company's reliance on a related-party pharmacy and regulatory compliance under Section 503A of the FFD&C Act introduces operational and regulatory risks that may affect its competitive position. The company's limited operating history and recurring losses also constrain its moat strength.

• Nasdaq Listing Compliance Risk: Mangoceuticals is not currently in compliance with Nasdaq's minimum bid price requirement and has received a notification letter with a deadline to regain compliance by August 3, 2026. Failure to comply may result in delisting and reduced market liquidity.
• Regulatory Risk Related to Compounding and Telehealth: The company's reliance on a related-party pharmacy operating under Section 503A of the FFD&C Act and telehealth-enabled prescribing exposes it to regulatory scrutiny. FDA enforcement actions or determinations that the business model exceeds compounding exemptions could lead to sanctions, increased costs, or discontinuation of products.
• Financial and Liquidity Risk: The company has recurring net losses, an accumulated deficit, and liquidity ratios indicating current liabilities exceed current assets. Additional capital is needed to support operations, and there is uncertainty regarding availability and terms of future financing.
• Operational Risks from Third-Party Dependencies: Mangoceuticals depends on third-party transportation providers for product shipments and a related-party pharmacy for compounding services. Disruptions or changes in these relationships could adversely affect operations and customer fulfillment.
• Legal and Litigation Risks: The company may face claims, litigation, and regulatory investigations related to its products and operations, which could result in legal costs, operational disruptions, and reputational harm.
• Cybersecurity and Data Privacy Risks: Reliance on data and information systems exposes the company to risks of security breaches, data loss, and privacy violations, which could harm reputation and result in regulatory penalties.

• Mangoceuticals, Inc. operates in the pharmaceutical and wellness sectors with a focus on compounded pharmaceutical products and nutraceuticals.
• The company relies on a related-party pharmacy, Epiq Scripts, LLC, which is 52% owned and controlled by the CEO Jacob D. Cohen, to provide pharmacy and compounding services under a Master Services Agreement and Consulting Agreement.
• Epiq Scripts holds licenses in 49 states and the District of Columbia, with an application pending for Alabama, limiting sales to licensed states.
• Mangoceuticals has entered into multiple consulting and service agreements with Epiq Scripts and other service providers such as Greentree Financial Group for bookkeeping and compliance.
• The company has a wholly-owned subsidiary, Mango & Peaches, which holds substantially all of the company's assets including international subsidiaries MangoRx Mexico and MangoRx UK.
• Mangoceuticals has launched various product lines and brands including PeachesRx, a women's telehealth brand for wellness and GLP-1 treatments, and has expanded into the wellness pouch market with leadership appointments.
• The company has acquired intellectual property assets from Smokeless Technology Corp. to expand into the oral pouch delivery market.
• Mangoceuticals secured exclusive rights for the plant-based nutriceutical Diabetinol® targeting pre-diabetes and weight management in the U.S. and Canada.
• The company is advancing antiviral and respiratory illness prevention research targeting avian influenza and poultry respiratory diseases, reporting 100% survival rates in field studies of MGX-0024.
• Mangoceuticals has signed exclusive distribution agreements for its Dermytol® skincare line.
• Financial snapshot as of 2026-03-31 shows cash and equivalents of $174,562, current assets of $212,472, current liabilities of $737,606, resulting in a current ratio of 0.29 and cash ratio of 0.24.
• Revenue for the quarter ended 2026-03-31 was $67,864 with a net loss of $3,403,150 and basic and diluted EPS of -$0.22.
• The company has experienced recurring net losses and an accumulated deficit, with significant operating expenses related to marketing, product development, and intellectual property investments.
• Mangoceuticals is not currently in compliance with Nasdaq's minimum bid price requirement and has received a notification letter with a compliance deadline of August 3, 2026.
• The company effected a 1-for-15 reverse stock split in October 2024 to address prior non-compliance with Nasdaq listing standards.
• The business model involves telehealth-enabled prescribing and compounding under Section 503A of the FFD&C Act, which carries regulatory risks due to FDA scrutiny of compounding pharmacies and telehealth practices.
• Risks include potential loss of compounding exemption if prescriptions are deemed invalid, regulatory enforcement actions, and operational disruptions.
• The company depends on third-party transportation providers for product shipments, which exposes it to risks of shipping delays and increased costs.
• Mangoceuticals has limited operating history and limited revenues to date, with ongoing needs for additional capital to support operations and growth.
• The company faces risks related to counterfeit products, legal claims, regulatory compliance, and cybersecurity threats.
• Mangoceuticals has a history of entering into strategic acquisitions and partnerships to expand its product offerings and market reach.